At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 56 enrolled
Drug / intervention
Eribulin mesylatedrug
Likely dose
Eribulin mesylate 1.4 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Eribulin mesylate for Locally Recurrent and Metastatic Breast Cancer ( HER2 Negative). Completed, enrolled 56 participants across 17 sites.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of single-agent eribulin mesylate for first-line treatment of subjects with locally recurrent or metastatic breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2010
Enrollment StartFeb 2011
Primary CompletionMar 2012
Study CompletionAug 2013
TodayJul 2026
First PostedDec 29, 2010
Enrollment StartFeb 1, 2011
Primary CompletionMar 1, 2012
Study CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.5 years ago
Interventions
Eribulin mesylatedrug
Eribulin mesylate 1.4 mg/m2 will be administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.